A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

NCT00746746 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: HyperAcute vaccine
DRUG: Pegylated Interferon-Alpha 2b

Sponsor

Ochsner Health System

Collaborators

[object Object]